Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: Results over 6 years

Francis De Zegher, Marc V L Du Caju, Claudine Heinrichs, Marc Maes, Jean De Schepper, Margareta Craen, Karin Vanweser, Paul Malvaux, Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Most children born small for gestational age (SGA) normalize their size through spontaneous catch-up growth within the first 2 yr after birth. Some SGA children fail to do so and maintain an abnormally short stature throughout childhood. We have previously reported that high dose GH treatment (66 or 100 μg/kg·day sc over 2 yr; age at start, 2-8 yr; n = 38) induces pronounced catch-up growth in short children born SGA, thereby normalizing their height and weight in childhood. Here, we report on the further prepubertal growth course of these children over the first 4 yr after withdrawal of early, high dose GH treatment. Of the 38 treated children, none developed precocious puberty, and 22 remained prepubertal. Mean age of the latter at start of GH was 4.4 yr, height was -3.7 SD score, and height after adjustment for midparental height was -2.9 SD score. Height increased by an average of 2.5 SD during the 2 yr of GH treatment and decreased by 0.4 and 0.3 SD, respectively, during the first and second year after GH withdrawal. Subsequently, when stature was not extremely short at the start (mean adjusted height SD score, -2.7; n = 13), no further GH treatment was given, and the adjusted height was stabilized around -1.0 SD score; when stature was very short at the start (mean adjusted height, -3.3 SD score; n = 9), a second course of GH treatment (66 μg/kg·day sc) was initiated either 2 yr (n = 5) or 3 yr (n = 4) after initial GH withdrawal. This second course was associated with renewed catch-up growth and also resulted in a mean adjusted height of -1.0 SD score. In each subgroup, the pattern of the weight course paralleled that of the height course; GH treatment was well tolerated. In conclusion, early, discontinuous, high dose GH treatment appears to be a safe and efficient option to normalize prepubertal height and weight in the majority of short SGA children. It remains to be examined whether the normalized stature will be maintained during pubertal development, either with or without further GH treatment.

Original languageEnglish (US)
Pages (from-to)1558-1561
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume84
Issue number5
StatePublished - 1999

Fingerprint

Growth Hormone
Gestational Age
Weights and Measures
Therapeutics
Growth
Precocious Puberty
Parturition

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

De Zegher, F., Du Caju, M. V. L., Heinrichs, C., Maes, M., De Schepper, J., Craen, M., ... Rosenfeld, R. R. (1999). Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: Results over 6 years. Journal of Clinical Endocrinology and Metabolism, 84(5), 1558-1561.

Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age : Results over 6 years. / De Zegher, Francis; Du Caju, Marc V L; Heinrichs, Claudine; Maes, Marc; De Schepper, Jean; Craen, Margareta; Vanweser, Karin; Malvaux, Paul; Rosenfeld, Ronald (Ron).

In: Journal of Clinical Endocrinology and Metabolism, Vol. 84, No. 5, 1999, p. 1558-1561.

Research output: Contribution to journalArticle

De Zegher, F, Du Caju, MVL, Heinrichs, C, Maes, M, De Schepper, J, Craen, M, Vanweser, K, Malvaux, P & Rosenfeld, RR 1999, 'Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: Results over 6 years', Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 5, pp. 1558-1561.
De Zegher, Francis ; Du Caju, Marc V L ; Heinrichs, Claudine ; Maes, Marc ; De Schepper, Jean ; Craen, Margareta ; Vanweser, Karin ; Malvaux, Paul ; Rosenfeld, Ronald (Ron). / Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age : Results over 6 years. In: Journal of Clinical Endocrinology and Metabolism. 1999 ; Vol. 84, No. 5. pp. 1558-1561.
@article{0781fb388da14583a79b395c9d5c7a1d,
title = "Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: Results over 6 years",
abstract = "Most children born small for gestational age (SGA) normalize their size through spontaneous catch-up growth within the first 2 yr after birth. Some SGA children fail to do so and maintain an abnormally short stature throughout childhood. We have previously reported that high dose GH treatment (66 or 100 μg/kg·day sc over 2 yr; age at start, 2-8 yr; n = 38) induces pronounced catch-up growth in short children born SGA, thereby normalizing their height and weight in childhood. Here, we report on the further prepubertal growth course of these children over the first 4 yr after withdrawal of early, high dose GH treatment. Of the 38 treated children, none developed precocious puberty, and 22 remained prepubertal. Mean age of the latter at start of GH was 4.4 yr, height was -3.7 SD score, and height after adjustment for midparental height was -2.9 SD score. Height increased by an average of 2.5 SD during the 2 yr of GH treatment and decreased by 0.4 and 0.3 SD, respectively, during the first and second year after GH withdrawal. Subsequently, when stature was not extremely short at the start (mean adjusted height SD score, -2.7; n = 13), no further GH treatment was given, and the adjusted height was stabilized around -1.0 SD score; when stature was very short at the start (mean adjusted height, -3.3 SD score; n = 9), a second course of GH treatment (66 μg/kg·day sc) was initiated either 2 yr (n = 5) or 3 yr (n = 4) after initial GH withdrawal. This second course was associated with renewed catch-up growth and also resulted in a mean adjusted height of -1.0 SD score. In each subgroup, the pattern of the weight course paralleled that of the height course; GH treatment was well tolerated. In conclusion, early, discontinuous, high dose GH treatment appears to be a safe and efficient option to normalize prepubertal height and weight in the majority of short SGA children. It remains to be examined whether the normalized stature will be maintained during pubertal development, either with or without further GH treatment.",
author = "{De Zegher}, Francis and {Du Caju}, {Marc V L} and Claudine Heinrichs and Marc Maes and {De Schepper}, Jean and Margareta Craen and Karin Vanweser and Paul Malvaux and Rosenfeld, {Ronald (Ron)}",
year = "1999",
language = "English (US)",
volume = "84",
pages = "1558--1561",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age

T2 - Results over 6 years

AU - De Zegher, Francis

AU - Du Caju, Marc V L

AU - Heinrichs, Claudine

AU - Maes, Marc

AU - De Schepper, Jean

AU - Craen, Margareta

AU - Vanweser, Karin

AU - Malvaux, Paul

AU - Rosenfeld, Ronald (Ron)

PY - 1999

Y1 - 1999

N2 - Most children born small for gestational age (SGA) normalize their size through spontaneous catch-up growth within the first 2 yr after birth. Some SGA children fail to do so and maintain an abnormally short stature throughout childhood. We have previously reported that high dose GH treatment (66 or 100 μg/kg·day sc over 2 yr; age at start, 2-8 yr; n = 38) induces pronounced catch-up growth in short children born SGA, thereby normalizing their height and weight in childhood. Here, we report on the further prepubertal growth course of these children over the first 4 yr after withdrawal of early, high dose GH treatment. Of the 38 treated children, none developed precocious puberty, and 22 remained prepubertal. Mean age of the latter at start of GH was 4.4 yr, height was -3.7 SD score, and height after adjustment for midparental height was -2.9 SD score. Height increased by an average of 2.5 SD during the 2 yr of GH treatment and decreased by 0.4 and 0.3 SD, respectively, during the first and second year after GH withdrawal. Subsequently, when stature was not extremely short at the start (mean adjusted height SD score, -2.7; n = 13), no further GH treatment was given, and the adjusted height was stabilized around -1.0 SD score; when stature was very short at the start (mean adjusted height, -3.3 SD score; n = 9), a second course of GH treatment (66 μg/kg·day sc) was initiated either 2 yr (n = 5) or 3 yr (n = 4) after initial GH withdrawal. This second course was associated with renewed catch-up growth and also resulted in a mean adjusted height of -1.0 SD score. In each subgroup, the pattern of the weight course paralleled that of the height course; GH treatment was well tolerated. In conclusion, early, discontinuous, high dose GH treatment appears to be a safe and efficient option to normalize prepubertal height and weight in the majority of short SGA children. It remains to be examined whether the normalized stature will be maintained during pubertal development, either with or without further GH treatment.

AB - Most children born small for gestational age (SGA) normalize their size through spontaneous catch-up growth within the first 2 yr after birth. Some SGA children fail to do so and maintain an abnormally short stature throughout childhood. We have previously reported that high dose GH treatment (66 or 100 μg/kg·day sc over 2 yr; age at start, 2-8 yr; n = 38) induces pronounced catch-up growth in short children born SGA, thereby normalizing their height and weight in childhood. Here, we report on the further prepubertal growth course of these children over the first 4 yr after withdrawal of early, high dose GH treatment. Of the 38 treated children, none developed precocious puberty, and 22 remained prepubertal. Mean age of the latter at start of GH was 4.4 yr, height was -3.7 SD score, and height after adjustment for midparental height was -2.9 SD score. Height increased by an average of 2.5 SD during the 2 yr of GH treatment and decreased by 0.4 and 0.3 SD, respectively, during the first and second year after GH withdrawal. Subsequently, when stature was not extremely short at the start (mean adjusted height SD score, -2.7; n = 13), no further GH treatment was given, and the adjusted height was stabilized around -1.0 SD score; when stature was very short at the start (mean adjusted height, -3.3 SD score; n = 9), a second course of GH treatment (66 μg/kg·day sc) was initiated either 2 yr (n = 5) or 3 yr (n = 4) after initial GH withdrawal. This second course was associated with renewed catch-up growth and also resulted in a mean adjusted height of -1.0 SD score. In each subgroup, the pattern of the weight course paralleled that of the height course; GH treatment was well tolerated. In conclusion, early, discontinuous, high dose GH treatment appears to be a safe and efficient option to normalize prepubertal height and weight in the majority of short SGA children. It remains to be examined whether the normalized stature will be maintained during pubertal development, either with or without further GH treatment.

UR - http://www.scopus.com/inward/record.url?scp=0033346650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033346650&partnerID=8YFLogxK

M3 - Article

C2 - 10323379

AN - SCOPUS:0033346650

VL - 84

SP - 1558

EP - 1561

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -